Anxiety Disorders
Anxiety disorders, affecting around 300 million people globally, are among the most prevalent mental health conditions. Emerging clinical research suggests that various psychedelics, including psilocybin, MDMA, and LSD, hold potential for alleviating anxiety symptoms through innovative therapeutic approaches.
Key Insights
- 1
Anxiety disorders represent the most prevalent mental health conditions, contributing to 3.4% of years lived with disability globally.
- 2
Psychedelics like psilocybin and MDMA demonstrate promise in alleviating end-of-life anxiety, showing sustained improvement in clinical trials.
- 3
Ketamine has been shown to provide rapid relief for anxiety symptoms in refractory cases, with significant efficacy observed soon after administration.
- 4
Clinical trials involving psychedelics are expanding rapidly, with organisations such as MAPS and various biotech companies leading the charge in research and development.
- 5
The intersection of anxiety and depression highlights the need for innovative treatments, with ongoing studies indicating that psychedelics can address dual diagnoses effectively.
What is Anxiety Disorders?
Anxiety is characterised by feelings of tension and excessive worry, often manifesting in symptoms that severely interfere with daily life and functioning. Common types of anxiety disorders include Generalised Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Obsessive-Compulsive Disorder (OCD), and Post-Traumatic Stress Disorder (PTSD). These conditions can coexist with depression, further complicating treatment options.
The DSM-V outlines anxiety disorders as conditions where individuals experience excessive anxiety and worry about varied topics for prolonged periods, leading to distressing symptoms such as restlessness, irritability, and sleep disturbances. With over 284 million individuals globally experiencing anxiety, the economic and personal burden is considerable.
Current Treatments
Standard treatment for anxiety disorders typically involves a combination of pharmacotherapy, including SSRIs and SNRIs, alongside psychotherapy. In cases of treatment-resistant anxiety, benzodiazepines and other anxiolytics are also employed; however, a significant proportion of patients remain unresponsive to these conventional therapies.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Anxiety Disorders.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Supported by multiple clinical trials indicating significant reductions in anxiety symptoms. | Large | Moderate | Consistent |
| MDMA Demonstrated efficacy in managing anxiety associated with PTSD and end-of-life distress. | Large | Moderate | Consistent |
| Ketamine Rapid anxiolytic effects observed in controlled trials, though effects are transient compared to classic psychedelics. | Medium | Moderate | Consistent |
| LSD Early results indicate potential efficacy, but more robust trials are needed. | Medium | Low | Inconsistent |
| Ayahuasca Limited research specifically addressing anxiety, though some anecdotal support exists. | Small | Very Low | Inconsistent |
Psilocybin and Anxiety Disorders
Psilocybin acts primarily as a 5HT-2A receptor agonist, promoting serotonin release in the brain. This activation is linked to reductions in negative emotional responses and alterations in entrenched thought patterns associated with anxiety, contributing to an improved sense of well-being and lower anxiety levels after therapy.
MDMA and Anxiety Disorders
MDMA promotes the release of serotonin, dopamine, and norepinephrine, enhancing mood and emotional openness. It is believed to reduce anxiety through its effects on the amygdala, allowing individuals to confront distressing feelings in a therapeutic context, evidenced by significant reductions in anxiety scores in clinical trials.
Ketamine and Anxiety Disorders
Ketamine serves as an NMDA receptor antagonist, leading to increased brain-derived neurotrophic factor (BDNF) secretion, which enhances synaptic plasticity. Its rapid onset of action results in swift alleviation of anxiety symptoms, particularly beneficial for patients with treatment-resistant anxiety disorders.
LSD and Anxiety Disorders
LSD functions through agonism at serotonin receptors, similar to psilocybin, and is thought to facilitate emotional processing and reduce anxiety through alterations in neural circuitry associated with the default mode network, ultimately contextualising fear and anxiety-provoking stimuli.
Clinical Outlook
The future of psychedelic treatments for anxiety disorders appears promising, driven by a robust pipeline of clinical trials and growing interest from biotech firms. As more data emerges, the establishment of evidence-based psychedelic therapy could revolutionise standard care protocols, offering new hope to millions who remain inadequately treated by conventional methods.
Industrial Landscape
Key players in the field include MindMed, which is developing LSD treatments for GAD in collaboration with the University of Basel, and Cybin, which is working on their proprietary CYB004 molecule targeting anxiety disorders. Non-profits like MAPS are significantly contributing to the research landscape for psychedelic-based therapies.
Quick Indicators
Related Topics
Organisations
Search →OPEN Foundation
Dutch nonprofit organizer in the psychedelic field, including stewardship of the ICPR conference series and related professional convenings.
Cybin
Cybin Inc. (founded 2019) is a Canadian clinical-stage biopharmaceutical company developing psychedelic-based therapeutics—now operating as Helus Pharma—focused on proprietary novel serotonergic agonists and deuterated psilocin analogs for mental health conditions.
Ohio State University
The Ohio State University is a public land-grant research university based in Columbus, Ohio, offering undergraduate, graduate, and professional programs and conducting research across many fields. It was founded as the Ohio Agricultural and Mechanical College and serves as a major educational and economic institution in Ohio.
COMPASS Pathways
COMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.
Diamond Therapeutics
Diamond Therapeutics is a private Canadian clinical-stage company pioneering sub-perceptual (non-hallucinogenic) psilocybin therapy. Their approach focuses on low-dose psilocybin that does not produce psychedelic experiences, enabling at-home outpatient administration — a differentiated strategy from the clinic-based, high-dose psychedelic-assisted therapy model. Founded in 2018 by CEO Judith Blumstock, Diamond completed a Phase 1 single ascending dose study in healthy volunteers (n=56, 7 cohorts, December 2022) establishing a safe non-hallucinogenic dose range. Their Phase 2a GAD programme received Health Canada approval in January 2023 — the first Health Canada NOL for a psychedelic trial in GAD — and enrolled first patients at Kingston Health Sciences Centre in 2025 in the first-ever at-home microdose psilocybin study. A parallel FDA-authorized Phase 2 demoralization trial is also underway at UAB. Diamond is funded by private investors and non-dilutive public grants, including a $1.1M+ CQDM/Brain Canada drug discovery consortium launched in May 2025.
Definium Therapeutics
Definium Therapeutics (formerly Mind Medicine / MindMed) is a late-stage clinical biopharmaceutical company headquartered in New York, founded in 2019 and rebranded in January 2026. Led by CEO Robert Barrow, the company applies scientific rigor to psychedelic-derived molecules to develop accessible, rapidly-acting psychiatric treatments. Its lead asset, DT120 ODT (formerly MM-120) — a pharmaceutically optimised formulation of lysergide D-tartrate (LSD) as an orally disintegrating tablet — has received FDA Breakthrough Therapy Designation for generalised anxiety disorder (GAD) and delivered compelling Phase 2b results: 65% clinical response rate and 48% remission at 12 weeks following a single dose. Three Phase 3 trials are currently underway: Voyage and Panorama (GAD) and Emerge (MDD, fully enrolled). Topline data from all three studies is expected in 2026, potentially positioning Definium for the first-ever FDA approval of an LSD-derived therapy. A second pipeline asset, DT402 (formerly MM402) — an MDMA-related compound — is in Phase 1 development for autism spectrum disorder.
National Institute of Mental Health (NIMH)
U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
Resilient Pharmaceuticals
Resilient Pharmaceuticals (formerly Lykos Therapeutics, formerly MAPS PBC) is a US-based public benefit corporation developing MDMA-assisted therapy for PTSD. It was founded in 2014 by MAPS (Multidisciplinary Association for Psychedelic Studies) as a commercial spinout to carry MAPS’ three decades of MDMA research through late-stage trials and regulatory approval. After completing two Phase 3 trials and filing an NDA in 2024, the FDA issued a Complete Response Letter (CRL) in August 2024, citing concerns about functional unblinding, durability of response, safety reporting at two trial sites, and the challenge of blinding psychedelic studies. The CRL requested a third Phase 3 trial. Following the rejection, the company laid off approximately 75% of staff. In May 2025, billionaire investors Antonio Gracias (Gracias Foundation) and Sir Christopher Hohn (TCI Fund) led a $50 million Series B recapitalisation, installing new leadership: CEO Mike Burke and CMO Javier Muniz. Rick Doblin, MAPS’ founder, remains supportive of the new direction. The company rebranded from Lykos Therapeutics to Resilient Pharmaceuticals on 28 August 2025, and continues to negotiate a path to FDA approval for MDMA-assisted therapy for PTSD.
MAPS
Nonprofit organizer and host of the Psychedelic Science conference series, alongside broader educational and policy programming.
University of Amsterdam
The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.
Ketamine Research Institute
The Ketamine Research Institute is a US-based clinical research organization developing precision medicine approaches to ketamine infusion therapy, studying optimized dosing protocols to treat depression and offering clinician training in evidence-based ketamine practice.
Portland Psychotherapy
Portland Psychotherapy is a Portland, Oregon clinic, research, and training center that integrates psychedelic science into evidence-based clinical practice, conducting clinical trials of MDMA-assisted therapy for social anxiety disorder and offering psychedelic integration services. Their distinctive model funds peer-reviewed research through clinical revenue, resulting in exceptionally well-trained therapists in psychedelic-assisted care.
People
Search →Federico Cavanna
Researcher in psychedelic science / neuroscientific researcher (exact current title not confidently verified)
He is a coauthor on multiple widely cited studies on psilocybin microdosing, DMT, and psychedelic use, helping characterize subjective, behavioral, and cognitive effects of psychedelics.
Robin Murphy
Researcher at the University of Auckland School of Pharmacy
She is a coauthor on multiple human psychedelic studies spanning LSD microdosing, sleep, and psilocybin/escitalopram comparisons, making her part of the team contributing to the modern evidence base for psychedelic medicine.
Hartej Gill
Researcher in mood disorders psychopharmacology at the University of Toronto / University Health Network
Notable for coauthoring multiple reviews and meta-analyses on ketamine, esketamine, suicidality, cognition, and psychedelic drug trials in psychiatric research.
Eduardo Schenberg
Neuroscientist and founder/director of Instituto Phaneros
A leading Brazilian psychedelic researcher known for clinical and translational work on ayahuasca, ibogaine, MDMA, and ethics/policy in psychedelic medicine.
Attila Szabo
Researcher in psychoneuroimmunology and psychedelic science; affiliated with the University of Oslo
He is a notable contributor to psychedelic immunology research, including widely cited work on DMT, 5-MeO-DMT, psilocybin, and immune modulation.
Jeanine Kamphuis
Psychiatrist and researcher at the Department for Mood Disorders, University Hospital Groningen (UMCG)
She studies ketamine, esketamine, and classic psychedelics for treatment-resistant psychiatric disorders, including depression, and is a coauthor on multiple psychedelic/ketamine reviews and clinical studies.
Henrik Jungaberle
Dr. sc. hum., CEO and founder of the MIND Foundation; Head of Development at OVID Clinic Berlin
He is a prominent European psychedelic research and implementation figure contributing to psilocybin clinical trials, harm reduction, and healthcare integration work.
Aaron Klaiber
Doctoral researcher at the University of Basel
He appears as an author on multiple controlled human psychedelic studies spanning DMT, mescaline, MDMA, LSD, and psilocybin, suggesting a substantial role in contemporary psychopharmacology research.
Joost Breeksema
Postdoctoral researcher and Executive Director of the OPEN Foundation
He is a prominent psychedelic researcher and advocate whose work helps shape evidence-based psychedelic policy, ethics, and patient-centered understanding of psychedelic and ketamine/esketamine treatments.
Juliana Rocha
Doutoranda em Ciências Médicas / Saúde Mental at the Ribeirão Preto Medical School, University of São Paulo
She is a recurring coauthor on clinical psychedelic studies, especially ayahuasca trials on social anxiety, emotion recognition, personality, and social cognition, helping expand the human evidence base for psychedelic-assisted psychiatric research.
Mathieu Seynaeve
Senior Medical Director and Head of Psychotherapy at Beckley Psytech
He is a clinical development leader behind multiple human studies of 5-MeO-DMT and psilocybin, including trials in alcohol use disorder, treatment-resistant depression, and headache disorders.
Kayla Teopiz
Researcher in psychiatry and ketamine/psychedelic medicine research; likely affiliated with the University of Toronto/Trillium Health Partners research network
Teopiz coauthors multiple systematic reviews and clinical studies on ketamine, esketamine, and psilocybin in depression and suicidality, helping synthesize the evidence base for psychedelic and glutamatergic treatments in psychiatry.
Connected Evidence
The latest clinical data and verified academic findings associated with Anxiety Disorders.